title: High-dose melphalan and the development of hematopoietic stem-cell transplantation: 25 years later.
authors.affiliation: Department of Medicine, University Hospitals Case Medical Center, Ireland Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA.
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.forename: Gordon L
authors.initials: GL
authors.lastname: Phillips
authors.forename: Roger H
authors.initials: RH
authors.lastname: Herzig
authors.forename: David D
authors.initials: DD
authors.lastname: Hurd
authors.forename: Steven N
authors.initials: SN
authors.lastname: Wolff
authors.forename: Geoffrey P
authors.initials: GP
authors.lastname: Herzig
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects; D003131:Combined Modality Therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008558:Melphalan / Q000008:administration & dosage* / Q000009:adverse effects; D009101:Multiple Myeloma / Q000628:therapy; D019653:Myeloablative Agonists / Q000008:administration & dosage / Q000009:adverse effects; D009369:Neoplasms / Q000628:therapy*; D009373:Neoplasms, Germ Cell and Embryonal / Q000628:therapy; D009447:Neuroblastoma / Q000628:therapy; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy
chemical_list: D018906:Antineoplastic Agents, Alkylating; D019653:Myeloablative Agonists; D008558:Melphalan